MedDataX Logo

The Effect of Erigeron Injection on Acute Cerebral Infarction Serum VEGF, MMP-9 and EPC Levels

NCT ID: NCT01926834

Last Updated: 2013-08-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-08-31

Study Completion Date

2014-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To study the effects of Erigeron Injection on human serum VEGF, MMP-9 and EPC levels after acute cerebral infarction,test is made by random double-blind controlled.patients with acute cerebral infarction were divided randomly into erigeron injection+aspirin group,aspirin group,and health people. The main indexes are the serum level of VEGF, MMP-9 and EPC.The review is made by the reference to NIHSS and so on. So, Erigeron Injection have the function of promoting angiogenesis in multiple targets through this test.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVE:

To study the effects of Erigeron Injection on human serum VEGF, MMP-9 and EPC levels after acute cerebral infarction.

METHOD:

40 patients with acute cerebral infarction(in accordance with the inclusion criteria) were divided randomly into erigeron injection+aspirin group,aspirin group,and 20 health people. Erigeron injection+aspirin group and aspirin group drew peripheral blood on the prior treatment,the posttreatment 1th, 3th and 7th day,and tested the level of VEGF, MMP-9 and EPC.Tested the health people one time.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebral Infarction

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

promoting angiogenesis in multiple targets herbal medicine traditional chinese medicine random clinical trial

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Erigeron Injection

Erigeron Injection, 30ml,qd,i.v., for 7 days

Group Type EXPERIMENTAL

Erigeron Injection

Intervention Type DRUG

Erigeron Injection, 30ml, iv, qd, for 7days

placebo

normal saline, 500ml,i.v.,qd, for 7 days

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

normal saline, 500ml,i.v.,qd, for 7 days

health volunteers

health volunteers, no drug to be given.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Erigeron Injection

Erigeron Injection, 30ml, iv, qd, for 7days

Intervention Type DRUG

placebo

normal saline, 500ml,i.v.,qd, for 7 days

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

normal saline, 500ml,i.v.,qd, for 7 days

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients aged no younger than 18yrs
* attack within 72 hours
* NIHSS score in the 2-25 points
* Ischemic Stroke occurred for the first time, or with a history of stroke disease but without sequelae
* Signed the informed consents

Exclusion Criteria

* patients aged younger than 18yrs
* Patients with tumor, coronary heart disease, valvular heart disease, psoriasis, rheumatism, hematologic diseases, infertility, varieties of acute inflammation
* Patients with severe cognitive impairment
* Refused to cooperate or been unable to cooperation for neurological disorders
* Cerebral hemorrhage or hemorrhagic cerebral infarction
* Unstable vital signs dued to massive cerebral infarction
* Patients with serious heart, liver and renal insufficiency
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Guangzhou University of Traditional Chinese Medicine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jianwen m Guo, doctor

Role: PRINCIPAL_INVESTIGATOR

Guangdong Province Hospital of Tradtional Chinese Medicine

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jianwen Guo, doctor

Role: CONTACT

Phone: 0086-13724899379

Email: [email protected]

Yefeng Cai, master

Role: CONTACT

Phone: (08620)81887233

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1201/01/006284

Identifier Type: -

Identifier Source: org_study_id